FATEFATE THERAPEUTICS INCvs its industry peers
A metric-by-metric comparison of FATE THERAPEUTICS INC against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FATE본 종목 | $245M#3 | — | 1.6x#4 | 36.9x#4 | -51.2%#3 | 26.8%#1 | -2222.4%#4 | -88.8%#5 | -102.3%#2 | — | 62.9%#1 | — |
| LCTX | $258M#1 | — | 4.2x#6 | 17.7x#3 | 53.2%#1 | -241.4%#6 | -251.6%#2 | -104.3%#6 | — | — | — | — |
| LXEO | $257M#2 | — | 1.1x#2 | 393.3x#5 | — | -1.7%#2 | -16706.0%#5 | -42.5%#4 | — | — | — | — |
| ALEC | $230M#4 | — | — | 10.9x#2 | -79.1%#4 | -20.2%#3 | -741.3%#3 | — | — | — | — | — |
| PLX | $209M#5 | 11.3x#1 | 2.9x#5 | 4.0x#1 | -1.2%#2 | -325.2%#7 | -10.4%#1 | -9.2%#1 | -12.3%#1 | 3#1 | 9.3%#3 | — |
| IKT | $208M#6 | — | 1.4x#3 | — | -100.0%#5 | -75.4%#5 | — | -31.5%#3 | — | — | — | — |
| ARTV | $206M#7 | — | 0.6x#1 | — | -100.0%#5 | -28.3%#4 | — | -24.1%#2 | — | — | 12.0%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-11-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice